Keros Therapeutics (KROS) Change in Receivables (2021 - 2025)
Keros Therapeutics (KROS) reported Change in Receivables of $75000.0 for Q4 2025, down 96.81% on a YoY basis from $2.4 million in Q4 2024, and up 100.61% quarter-over-quarter from -$12.3 million in Q3 2025.
Keros Therapeutics (KROS) Change in Receivables (2021 - 2025) Analysis & Trends
Keros Therapeutics has reported Change in Receivables for 5 years, with the latest figure at $75000.0 in Q4 2025.
- For the quarter ending Q4 2025, Change in Receivables fell 96.81% year-over-year to $75000.0; the trailing twelve-month figure through Dec 2025 stood at $825000.0 (down 68.26% YoY), and the FY2025 full-year result was $825000.0, down 68.26% from the prior year.
- Change in Receivables for Q4 2025 stood at $75000.0, up from -$12.3 million in the prior quarter.
- The five-year high for Change in Receivables was $18.0 million in Q4 2021, with the low at -$18.0 million in Q1 2022.
- Historically, Change in Receivables has averaged $274384.6 across 5 years, with a median of $83000.0 in 2024.
- The largest YoY upside for Change in Receivables was 17428.92% in 2025 against a maximum downside of 3309.38% in 2025.
- Keros Therapeutics' Change in Receivables stood at $18.0 million in 2021, then slumped by 200.0% to -$18.0 million in 2022, then soared by 100.79% to $143000.0 in 2023, then soared by 1546.15% to $2.4 million in 2024, then slumped by 96.81% to $75000.0 in 2025.
- The last three Change in Receivables figures came in at $75000.0 (Q4 2025), -$12.3 million (Q3 2025), and -$1.5 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 22,529.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -39.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -4.08 Mn |
| 10 | Keros Therapeutics | 399.01 Mn | 111.61 Mn | - | 75,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 75,000.00 |
| Dec 31, 2025 | 75,000.00 |
| Sep 30, 2025 | -12.32 Mn |
| Sep 30, 2025 | -12.32 Mn |
| Jun 30, 2025 | -1.48 Mn |
| Jun 30, 2025 | -1.48 Mn |
| Mar 31, 2025 | 14.55 Mn |
| Mar 31, 2025 | 14.55 Mn |
| Dec 31, 2024 | 2.35 Mn |
| Dec 31, 2024 | 2.35 Mn |
| Sep 30, 2024 | 384,000.00 |
| Sep 30, 2024 | 384,000.00 |
| Jun 30, 2024 | -222,000.00 |
| Jun 30, 2024 | -222,000.00 |
| Mar 31, 2024 | 83,000.00 |
| Mar 31, 2024 | 83,000.00 |
| Dec 31, 2023 | 143,000.00 |
| Dec 31, 2023 | 143,000.00 |
| Mar 31, 2022 | -18.00 Mn |
| Mar 31, 2022 | -18.00 Mn |